AIM ImmunoTech Inc.(AIM)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

AIM ImmunoTech Inc. (AIM) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AIM at 9.9/100 on a 32-signal composite quality model, placing it at rank #2,912 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), AIM ImmunoTech Inc. reports quarterly revenue of $26.0K, net income of $-3.8M. Top institutional holders of AIM by reported 13-F value include JANE STREET GROUP, Virtu Financial, MORGAN STANLEY, based on the most recent SEC filings. AIM trades on the NYSE exchange and files with the SEC under CIK 946644. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AIM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AIM ImmunoTech Inc. directly from SEC EDGAR.